ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease

OBJECTIVE: To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). METHODS: In this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurology
Main Authors: Cummings, Jeffrey L., Cohen, Sharon, van Dyck, Christopher H., Brody, Mark, Curtis, Craig, Cho, William, Ward, Michael, Friesenhahn, Michel, Rabe, Christina, Brunstein, Flavia, Quartino, Angelica, Honigberg, Lee A., Fuji, Reina N., Clayton, David, Mortensen, Deborah, Ho, Carole, Paul, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5962917/
https://ncbi.nlm.nih.gov/pubmed/29695589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000005550
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados